IN VIVO 31-P NMR STUDIES IN SCHIZOPHRENICS

由动物研究支持的临床研究表明，背部 前额叶皮质在精神分裂症患者认知缺陷中的观察。 到目前为止的生理研究表明额叶减少 脑血流量(氙气133)和2-脱氧葡萄糖摄取(正电子) 对部分精神分裂症患者进行放射断层扫描(PET)。相比之下， 自闭症的PET研究报告说，自闭症患者对2-脱氧葡萄糖的摄取增加 成年自闭症患者的额叶。31P核磁共振波谱提供了 高能磷酸盐和膜代谢的体内评价 直接和非侵入性地促进纵向研究。初步 这个实验室的31P核磁共振研究揭示了细胞膜的变化 8例首发、从未用药的精神分裂症患者的磷脂代谢 这与观察到的正常衰老惊人地相似。在……里面 此外，PCR值与病情严重程度呈正相关。 阳性症状。相似的磷脂但不同的高能 在5名智商正常的成人自闭症患者中观察到了磷酸盐的发现。 基于这些初步发现，本研究建议首先研究30 发病，入院时、4周、6周和12周从未给精神分裂症患者用药 进入研究的两个月和两年。结果在30个月中 将精神分裂症患者的结果与对照组(30例正常)进行比较 对照组和30名自闭症患者)在入境时以及在入境后1年和2年获得 进入。选择智商正常的成人自闭症患者作为对照组 这些自闭症患者有许多与精神分裂症相同的阴性症状， 有时被误诊为精神分裂症，但起病年龄不同 和一种不同的临床过程。

Clinical studies supported by animal research have implicated the dorsal prefrontal cortex in the cognitive deficits observed in schizophrenia. Physiological studies to date have demonstrated decreased frontal lobe cerebral blood flow (xenon 133) and 2-deoxyglucose uptake (positron emission tomography, PET) in some patients with schizophrenia. In contrast PET studies in autism have reported increased uptake of 2-deoxyglucose in the frontal lobes of adult autistic men. 31P NMR spectroscopy provides in vivo assessment of both high-energy phosphate and membrane metabolism directly and non-invasively facilitating longitudinal studies. Preliminary 31P NMR studies from this laboratory reveal alterations in membrane phospholipid metabolism in 8 first episode, never medicated schizophrenics that are strikingly similar to those observed with normal aging. In addition the levels of PCr have a positive correlation with the severity of positive symptoms. Similar phospholipid but different high energy phosphate findings have been observed in 5 normal IQ adult autistics. Based on these preliminary findings, this study proposes to study 30 first episode, never medicated schizophrenics at entry and at 4 weeks, 6 and 12 months and 2 years after entry into the study. Results in the 30 schizophrenics will be compared with results in controls (30 normal controls and 30 autistics) obtained at entry and at 1 and 2 years after entry. The normal IQ adult autistics are chosen as a comparison group as these autistics share many of the negative symptoms with schizophrenia, are sometimes misdiagnosed as schizophrenia but have a different age of onset and a different clinical course.